Cancer Research

Clay Siegall leads Seattle Genetics to top of cancer research industry

In the world of cancer research, few names stand out with such distinction is at of Clay Siegall. After founding Seattle Genetics in 1998, Dr. Siegall has established himself as one of the leading cancer research entrepreneurs in the pharmaceutical industry. With the first ever antibody drug conjugate that was approved by the FDA for use in actual cancer treatment, Seattle Genetics is quickly transforming the way in which cancer is treated in the United States and throughout the world.

Dr. Siegall first became interested in cancer research at a fairly young age. While still in college, he had a family member that went through a period of chemotherapy as result of developing a rare form of cancer. What caught Dr. Siegall’s attention wasn’t so much the cancer itself, but the treatment regimen, specifically its total brutality. The family member was sick all the time and could barely function. At one point, they nearly died, not as a result of the cancer itself but as a result of developing anemia secondary to the poisonous chemotherapy that was being pumped through their veins.

This made Dr. Siegall realize that there must be a better way than the current regimens of cancer treatment. Between the outright poison of chemotherapy and the radical surgeries, including amputations, that were then used for the treatment of many forms of cancer, Dr. Siegall knew that there must be a way to restore the sick patients to health that didn’t involve the permanent maiming and scarring that the treatments in the mid-80s often entailed.

He went on to receive a MS from the University of Maryland in biology, and then a PhD in genetics from George Washington University. After successfully completing graduate school, he was hired by the national cancer institute as a junior researcher. There he worked on a number of exciting new drugs, including a category that is broadly known as targeted cancer therapies. These drugs seek to identify and destroy the tumor without systemically releasing large amounts of poisonous chemotherapy into the body.

After a stint with the national cancer institute, Dr. Siegall was recruited by Bristol-Myers Squibb as a senior researcher. It was there that he first began working on the completely novel form of targeted cancer therapy called antibody drug conjugates.

Cancer Research

Clay Siegall And Seattle Genetics: Fighting The War On Cancer

Mr. Clay Siegall graduated from the University of Maryland with a Bachelor degree in Science specifically Zoology and later attended George Washington University to receive a PhD in genetics. Mr. Siegall’s area of expertise is developing cancer treatments, specifically fighting the growth of cancer cells. With his passion to help the fight the growth of cancer, Mr. Siegall has led Seattle Genetics in creating antibody drug conjugates (ADCs) to treat cancer and serves on the board of three other pharmaceutical companies in addition to serving as president for Seattle Genetics.

Co Founded in 1998 by Clay Siegall, Seattle Genetics has taken the war on cancer to the next level. Seattle Genetics has become the leader in developing ADCs and has licensed the technology to several other pharmaceutical companies such as: Pfizer, and Glaxo-Smith Kline to help more scientists in the quest of understanding the pattern of cancer cells and how to eradicate them.

ADCs are important to the treatment of cancer due to the compound of three specific items:

The Antibody- targets specific protein markers on the surface of the affected cells and binds to the cell.

The Chemotherapy- released directly into the affected cells once the antibody has bound itself to the cell.

The Link- this binds the antibody to the chemotherapy so that the chemotherapy is not released until it is in the cancer cell.

ADCs are effective at targeting just cancer cells, leaving normal cells alone for the most part resulting in a faster healing time for patients. This relatively new type of treatment is very cancer specific and is currently being studied in eight types of cancer thus far. These types include: Breast, Lung, Prostate, Liver, Colon, Pancreatic, Myeloma, and Melanoma.

Seattle Genetics is broadening their horizons with more ADC testing on other types of cancer such as Leukemia. They have over eight hundred employees and are committed to treating patients with integrity, offering a much better standard of cancer treatment than traditional treatment methods.

http://www.xconomy.com/author/csiegall/

http://www.bloomberg.com/research/stocks/people/person.asp?personId=607509&privcapId=34145